NfL
GFAP
Optical coherence tomography (OCT)
Immune profiling and PRLs
Eye-movement biomarkers
Read More
Latest News
CLINICAL CASES IN MS: A PATIENT WITH WORSENING FATIGUE AND NEW MOBILITY PROBLEMS
March 13, 2025Click here to watch Dr. Daniel Selchen discuss the case and the responses to the survey.
D.C. is a 41-year-old woman diagnosed with multiple sclerosis 14 years ago. She was treated initially with a beta interferon. She experienced ongoing disease activity and was transitioned to natalizumab 10 years ago. She was completely stable for six years. She was switched to fingolimod after a significant change in JCV index. She had no MRI changes on natalizumab and a few new MRI lesions on fingolimod. She had no new lesions while on natalizumab and few MRI changes on fingolimod. Her EDSS score a year ago was 1.5 (vision 1, sensory 1, bladder 1).
ACTRIMS Forum 2025 highlights – Focus on ofatumumab
March 10, 2025ACTRIMS Forum 2025 Highlights – Saturday, March 1, 2025
March 1, 2025The following summarizes some of the highlights from Day 2 if the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2025.